About Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Jazz Pharmaceuticals Plc is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments primarily in the areas of sleep medicine, neurology, and hematology. The company is dedicated to addressing significant unmet medical needs by creating therapies that improve patient outcomes and quality of life. Jazz Pharma's portfolio includes a range of pharmaceutical products designed to treat various conditions, with a particular emphasis on disorders related to sleep and central nervous system disorders. Through its research and development initiatives, the company aims to advance the scientific understanding of these conditions and contribute to the broader healthcare landscape. Read More
Alkermes agrees to acquire Avadel for $2.1 billion, adding the successful Lumryz drug and accelerating entry into sleep medicine. Jazz litigation settled.
DUBLIN, IRELAND – October 22, 2025 – Avadel Pharmaceuticals (NASDAQ: AVDL) shareholders are celebrating today as Alkermes plc (NASDAQ: ALKS) announced a definitive agreement to acquire the company for a staggering $2.1 billion. The news sent Avadel's stock price soaring in premarket trading, reflecting a significant premium offered to its investors.
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca (lurbinectedin) and Roche's (SIX: ROG, OTCQX: RHHBY) Tecentriq (atezolizumab), along with its subcutaneous formulation Tecentriq Hybreza. This landmark decision sanctions
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.23 billion at the midpoint. Its non-GAAP loss of $8.25 per share was 32.1% below analysts’ consensus estimates.
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ)
jumped 4.8% in the afternoon session after the company received accelerated approval from the U.S. Food and Drug Administration (FDA) for Modeyso, its new treatment for a rare brain tumor.
Jazz Pharmaceuticals (JAZZ) is a value stock with strong fundamentals, trading below industry averages in P/E and EV/EBITDA, while maintaining high profitability and steady growth potential.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.23 billion at the midpoint. Its non-GAAP loss of $8.25 per share was 32.1% below analysts’ consensus estimates.
Jazz Pharmaceuticals Q2 2025 results miss revenue and EPS estimates, shares drop 6%. New CEO Renee Gala takes helm amid Xywav growth but investor concerns linger.
